IDH1 and central nervous system cancer: Importantly, both IDH1 mutation and SVZ-negative tumors enabled favorable patient outcomes and longer time to relapse, whereas IDH1-wild glioma with SVZ-positive displayed a significantly worse prognosis and shorter time to relapse (Figures 4A, B).